The National Hemophilia Foundation (NHF) is pleased to announce that two educational activities in the “Clinical Advances in Gene Therapy for Hemophilia” series have been recertified, and will therefore be valid for credit through September 6, 2020. The series is presented through a collaboration between Medscape, NHF, the European Haemophilia Consortium and the World Federation of Hemophilia. The program is supported by an independent educational grant from BioMarin.
The recertified activities are:
“The Science of Gene Therapy for Hemophilia,” which will examine the technology behind the emerging approaches to gene therapy in hemophilia. Upon completion, participants will have increased knowledge regarding the use of gene therapy for hemophilia and of the mechanisms of gene therapy for hemophilia that affect immunity, efficacy and safety.
Authors: Glenn F. Pierce, MD, PhD
CME / ABIM MOC Released: 8/3/2018; Reviewed and Renewed: 9/6/2019
Valid for credit through: 9/6/2020
“Why Gene Therapy for Hemophilia? Exploring the Challenges of Current Therapies,” is a discussion about the current clinical challenges associated with the use of factor replacement therapy in hemophilia patients and the part gene therapy may play in the future. Upon completion of this activity, participants will have increased knowledge regarding the potential role of gene therapy to address challenges in current hemophilia treatment.
Authors: John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH;
Johnny Mahlangu, BSc, MBBCh, MMed, FCPath
CME / ABIM MOC Released: 8/23/2018; Reviewed and Renewed: 9/6/2019
Valid for credit through: 9/6/2020
Access this link to visit the “Clinical Advances in Gene Therapy for Hemophilia” homepage. If you are not already registered, simply go to Medscape.org where registration is straightforward and free of charge.
